FibroGen, Inc

Add to watchlist
€21.17
Last updated:06/15/2021
1FG: F
FibroGen, Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical… Show more

P/E ratio
45.63x
vs. 81.30x forward

Price is 45.63x times more than EPS €0.464 which eaquals €21.17

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Company profile
CEO
Mr. Enrique A. Conterno
Market capitalization
Small (1.94B)